EntryPoint Capital’s Mereo BioPharma MREO Stock Holding History

EntryPoint Capital’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-400,700	Closed	-$167K	–	861
2025 Q4	$167K	Buy	+400,700	New	+$763K	0.07%	579

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $712M AUM

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

EntryPoint Capital's MREO Position: Q1 2026 in Review

EntryPoint Capital sold out of Mereo BioPharma (MREO) in Q1 2026, closing a stake of 400,700 shares — an estimated $167K sold.

EntryPoint Capital first reported a position in MREO in Q4 2025 and held it in 1 quarter. The position peaked at $167K in Q4 2025. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

EntryPoint Capital reported no remaining Mereo BioPharma position as of Q1 2026 after selling out during the quarter.
EntryPoint Capital sold 400,700 Mereo BioPharma shares in Q1 2026, an estimated $167K.
EntryPoint Capital first reported a position in Mereo BioPharma in Q4 2025 and held it in 1 quarter.
EntryPoint Capital's Mereo BioPharma position peaked at $167K in Q4 2025.
63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.